Hua Xuande & family (#3152)
- $ 1 B
- Pharmaceuticals
- China
- M
- 82 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Hua Xuande chairs Zhejiang ZoneBanner Jiuzhou Group, which controls Shanghai-listed pharmaceutical supplier Zhejiang Jiuzhou Pharmaceutical. Hua's daughter, Hua Lirong, chairs Zhejiang Jiuzhou Pharmaceutical. In September 2019, Jiuzhou Pharmaceutical acquired U.S. pharmaceutical ingredient firm PharmAgra Labs for a reported $16 million. In 2019 Jiuzhou also took over a Chinese subsidiary of Swiss pharmaceutical maker Novartis to help expand its production.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Hua Xuande & family’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Hua Xuande & family’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $1.1B
(May 4, 2026)
© Iconic Billionaires